| 91.08 0.87 (0.96%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 107.77 | 1-year : | 109.38 |
| Resists | First : | 92.26 | Second : | 93.65 |
| Pivot price | 91.96 |
|||
| Supports | First : | 90.03 | Second : | 74.9 |
| MAs | MA(5) : | 91.5 |
MA(20) : | 92.04  |
| MA(100) : | 84.64 |
MA(250) : | 84.62 |
|
| MACD | MACD : | 0.6 |
Signal : | 1 |
| %K %D | K(14,3) : | 21.1 |
D(3) : | 32.3 |
| RSI | RSI(14): 50.9 |
|||
| 52-week | High : | 93.65 | Low : | 72.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PJP ] has closed above bottom band by 25.5%. Bollinger Bands are 25.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 91.29 - 91.9 | 91.9 - 92.44 |
| Low: | 88.96 - 89.75 | 89.75 - 90.46 |
| Close: | 89.88 - 91.1 | 91.1 - 92.21 |
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Thu, 25 Sep 2025
Goldman Sachs Group Inc. Reduces Stock Holdings in Invesco Pharmaceuticals ETF $PJP - Defense World
Thu, 10 Jul 2025
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now? - Yahoo Finance
Wed, 18 Jun 2025
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? - Yahoo Finance
Mon, 12 May 2025
Pharma ETFs in Focus on Trump's Drug Price Overhaul - TradingView
Tue, 27 Jun 2023
Best Pharma ETFs - Benzinga
Thu, 18 May 2023
Want to Invest in Pharmaceutical Stocks but Don't Know How? Try This ETF. - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|